Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease

Hepatology Research

Volumn 47, Issue 9, 2017, Pages 882-889

  Seki, Kojiro ^a   Shima, Toshihide ^a   Oya, Hirohisa ^a   Mitsumoto, Yasuhide ^a   Mizuno, Masayuki ^a   Okanoue, Takeshi ^a  

^a Saiseikai Suita Hospital   (Japan)

Author keywords

FibroScan; liver fibrosis; non alcoholic fatty liver disease; non alcoholic steatohepatitis; transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; COLLAGEN TYPE 7;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELASTOGRAPH; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY;

EID: 85005932165     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12829     Document Type: Article

References (35)

1. Watanabe S, Hashimoto E, Ikejima K et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 2015; 45: 363–377.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathologic severity. Gastroenterology 1999; 116: 1413–1419.
4. Yasui K, Hashimoto E, Komorizono Y et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma: a multicenter study in Japan. Clin Gastroenterol Hepatol 2011; 9: 428–433.
5. Anglo P, Hui IM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–854.
6. Wai CT, Greeson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–526.
7. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–1325.
8. Sandirin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705–1713.
9. Kattaneh A, Marcellin P, Douvin C et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46: 628–634.
10. Wrong GL. Transient elastography: kill two birds with one stone? World J Hepatol 2013; 27: 264–274.
11. Shaheen AA, Wan AF, Myeres RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589–2600.
12. Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403–408.
13. Ganne-Carrie N, Ziol M, de Ledinghen V et al. Accuracy of liver stiffness measurement for diagnosis of cirrhosis in patients with chronic liver disease. Hepatology 2006; 44: 1511–1517.
14. Ogawa E, Furusyo N, Murata M et al. Longitudinal quantitative assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res 2011; 41: 1178–1188.
15. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon α-2b and ribavirin. Antiviral Res 2009; 83: 127–134.
16. Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res 2015; 45: 142–151.
17. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237–264.
18. Yoneda M, Yoneda M, Mawatari H et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371–378.
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
20. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911–918.
21. Nobili V, Vizzutti F, Arena U et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442–448.
22. Lupsor M, Badea R, Stefanescu H et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19: 53–60.
23. Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic liver disease. Hepatology 2010; 51: 454–462.
24. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350–1360.
25. Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199–208.
26. Wong VW, Vergniol J, Wong GL et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862–1871.
27. Mahadeva S, Mahfudz AS, Vijayanathan A, Goh KL, Kulenthran A, Cheah PL. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. J Dig Dis 2013; 14: 604–610.
28. Kumar R, Rastogi A, Sharma MK et al. Liver stiffness measurement in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013; 58: 265–274.
29. Tapper EB, Challies T, Nasser I et al. The performance of vibration controlled transient elastography in a US cohort of patients with non-alcoholic fatty liver disease. Am J Gastroenterol 2016; 111: 677–684.
30. Okajima A, Sumida Y, Taketani H et al. Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. Hepatol Res 2016. DOI:10.1111/hepr.12793.
31. Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med 2010; 25: 49–67.
32. Petta S, Maida M, Macaluso FS et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015; 62: 1101–1110.
33. Vizzutti F, Arena U, Romanelli R et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45: 1290–1297.
34. Yoshimura K, Okanoue T, Ebise H et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016; 63: 462–473.
35. Mizuno M, Shima T, Oya H et al. Classification of patients with nonalcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with that using liver histology and other fibrosis markers. Hepatol Res 2016. DOI:10.1111/hepr.12710.